1661 related articles for article (PubMed ID: 11312329)
1. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
2. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
[TBL] [Abstract][Full Text] [Related]
3. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
4. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
Liang B; Kabatova B; Kabat J; Dorward DW; Liu X; Surman S; Liu X; Moseman AP; Buchholz UJ; Collins PL; Munir S
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651356
[TBL] [Abstract][Full Text] [Related]
5. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
[TBL] [Abstract][Full Text] [Related]
6. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
8. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
[TBL] [Abstract][Full Text] [Related]
9. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
Liang B; Munir S; Amaro-Carambot E; Surman S; Mackow N; Yang L; Buchholz UJ; Collins PL; Schaap-Nutt A
J Virol; 2014 Apr; 88(8):4237-50. PubMed ID: 24478424
[TBL] [Abstract][Full Text] [Related]
10. Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
Liu X; Liang B; Liu X; Amaro-Carambot E; Surman S; Kwong PD; Graham BS; Collins PL; Munir S
PLoS One; 2020; 15(2):e0228572. PubMed ID: 32045432
[TBL] [Abstract][Full Text] [Related]
11. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.
Tang RS; MacPhail M; Schickli JH; Kaur J; Robinson CL; Lawlor HA; Guzzetta JM; Spaete RR; Haller AA
J Virol; 2004 Oct; 78(20):11198-207. PubMed ID: 15452239
[TBL] [Abstract][Full Text] [Related]
12. Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.
Haller AA; Mitiku M; MacPhail M
J Gen Virol; 2003 Aug; 84(Pt 8):2153-2162. PubMed ID: 12867647
[TBL] [Abstract][Full Text] [Related]
13. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
[TBL] [Abstract][Full Text] [Related]
14. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.
Zhan X; Slobod KS; Krishnamurthy S; Luque LE; Takimoto T; Jones B; Surman S; Russell CJ; Portner A; Hurwitz JL
Vaccine; 2008 Jun; 26(27-28):3480-8. PubMed ID: 18499307
[TBL] [Abstract][Full Text] [Related]
15. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.
Nelson CL; Tang RS; Stillman EA
Vaccine; 2013 Aug; 31(36):3756-62. PubMed ID: 23623857
[TBL] [Abstract][Full Text] [Related]
16. Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
Brock LG; Liu X; Liang B; Lingemann M; Liu X; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925656
[TBL] [Abstract][Full Text] [Related]
17. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
18. A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.
Bailly JE; McAuliffe JM; Durbin AP; Elkins WR; Collins PL; Murphy BR
J Virol; 2000 Apr; 74(7):3188-95. PubMed ID: 10708435
[TBL] [Abstract][Full Text] [Related]
19. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.
Skiadopoulos MH; Surman SR; Riggs JM; Collins PL; Murphy BR
J Virol; 2001 Nov; 75(21):10498-504. PubMed ID: 11581420
[TBL] [Abstract][Full Text] [Related]
20. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.
Tang RS; Spaete RR; Thompson MW; MacPhail M; Guzzetta JM; Ryan PC; Reisinger K; Chandler P; Hilty M; Walker RE; Gomez MM; Losonsky GA
Vaccine; 2008 Nov; 26(50):6373-82. PubMed ID: 18822334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
